# Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism.

> **NCT03199430** · PHASE4 · COMPLETED · sponsor: **Swansea University** · enrollment: 8 (actual)

## Conditions studied

- EGCG Influence on Catecholamine Metabolism

## Interventions

- **DIETARY_SUPPLEMENT:** Epigallocatechin gallate
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03199430
- **Lead sponsor:** Swansea University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-01
- **Final completion:** 2016-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199430, "Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03199430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*